Sort
10,766 grants matching “checkpoint inhibitor”
Paving the way for bystander T cell immunotherapies
$113,937Nicholas Joseph Maurice · University Of Minnesota · K99 · FY2025 · CA
Immune-Related Adverse Events in Melanoma Patients Receiving Adjuvant Immune Checkpoint Inhibitor Therapy
$113,868Noha Abdelwahab Hassan Ali Hassan · University Of Tx Md Anderson Can Ctr · K01 · FY2021 · AI
Immune-Related Adverse Events in Melanoma Patients Receiving Adjuvant Immune Checkpoint Inhibitor Therapy
$113,868Noha Abdelwahab Hassan Ali Hassan · University Of Tx Md Anderson Can Ctr · K01 · FY2024 · AI
Immune-Related Adverse Events in Melanoma Patients Receiving Adjuvant Immune Checkpoint Inhibitor Therapy
$113,868Noha Abdelwahab Hassan Ali Hassan · University Of Tx Md Anderson Can Ctr · K01 · FY2023 · AI
Immune-Related Adverse Events in Melanoma Patients Receiving Adjuvant Immune Checkpoint Inhibitor Therapy
$113,868Noha Abdelwahab Hassan Ali Hassan · Cleveland Clinic Lerner Com-Cwru · K01 · FY2025 · AI
Immune-Related Adverse Events in Melanoma Patients Receiving Adjuvant Immune Checkpoint Inhibitor Therapy
$113,868Noha Abdelwahab Hassan Ali Hassan · University Of Tx Md Anderson Can Ctr · K01 · FY2022 · AI
An innate immune checkpoint in cancer immunotherapy.
$113,240Carla Rothlin · Yale University · R01 · FY2018 · CA
Sumikiâs Acid, a de novo Dietary Compound Generated from Food Processing, Reprograms NK Cells for Cancer Immunoprevention
$113,203Zhicheng Xie · University Of Chicago · K99 · FY2025 · CA
Dendritic cell lysosomes in immune checkpoint inhibitor-associated myocarditis
$112,822Kenji Rowel Lim · Washington University · K99 · FY2025 · HL
PD-1 tumor suppressor mechanims in peripheral T-cell lymphoma
$112,613Tim Wartewig · Yale University · K99 · FY2023 · CA
Target validation of CD206 activators
$112,360Juan Marugan · National Center For Advancing Translational Sciences · ZIA · FY2020 · TR
Targeting PTGIR-Prostacyclin Signaling to Overcome T Cell Exhaustion and Enhance Anti-Tumor Immunity
$112,234Michael Dahabieh · Van Andel Research Institute · K99 · FY2025 · CA
Development Project 2
$112,151Beti Thompson · Fred Hutchinson Cancer Research Center · U54 · FY2015 · CA
Overcoming treatment-resistant gynecological cancers by combination of DNA damage response inhibitors
$112,052Haineng Xu · University Of Pennsylvania · R50 · FY2025 · CA
Overcoming treatment-resistant gynecological cancers by combination of DNA damage response inhibitors
$112,052Haineng Xu · University Of Pennsylvania · R50 · FY2024 · CA
A physical sciences approach to investigate the role of exosomes in metastatic progression
$111,985Ravi Radhakrishnan · University Of Pennsylvania · U01 · FY2024 · CA
Mitomycin C (MC) and 10-decarbamoyl MC Signaling to p53 and Family Members
$111,667Hunter College · S06 · FY2005 · GM
Regulation of translation through the human translation initiation factor eIF5B
$111,020Assen G Marintchev · Harvard Medical School · K01 · FY2007 · CA
CAREER DEVELOPMENT PROGRAM
$111,000Peter T Scardino · Sloan-Kettering Inst Can Research · P50 · FY2007 · CA
P3 - Mechanism-Based Use of Chk1 Inhibitors in Pancreas Cancer
$110,810Theodore S Lawrence · University Of Michigan At Ann Arbor · P50 · FY2010 · CA
P3 - Mechanism-Based Use of Chk1 Inhibitors in Pancreas Cancer
$110,356Theodore S Lawrence · University Of Michigan At Ann Arbor · P50 · FY2011 · CA
ASPECTS OF UTERINE CELL CYCLE REGULATION IN IMPLANTATION
$110,148University Of Kansas Medical Center · R01 · FY2002 · HD
Regulation of PDAC metabolism and immunity by collagen and its cleavage products
$110,000Michael Karin · University Of California, San Diego · U01 · FY2025 · CA
Translational and Clinical Sciences
$109,954Heinz Josef Lenz · University Of Southern California · P30 · FY2024 · CA
Defining the role of macropinocytosis in solid tumor growth and therapeutic resistance
$109,595Aimee L Edinger · University Of California-Irvine · R01 · FY2022 · CA